linjc16/ctgov huggingface dataset:
The Effects of the Endocrine System on Endometrial Cancer

Study Overview
=================
Brief Summary
-----------------
Endometrial cancer usually begins in the endometrium, which is the tissue lining of the uterus. Endometrial cancer is the most commonly diagnosed gynaecological malignancy in Australia. It affects 1 in 80 Australian women and there are about 1400 new cases and 260 deaths from the disease every year. Most affected women are aged between 50 and 70 years. The purpose of this study is to investigate the possible role of the endocrine system in the regulation of human endometrial cancer. By looking at the laboratory results of people with endometrial cancer and also those without endometrial cancer we hope to gain a better understanding of how endometrial cancer develops and progresses. This may lead to the development of new, effective therapies for endometrial cancer.

Official Title
-----------------
Expression and Function of Ghrelin and Its Receptor, Growth Hormone Secretagogue Receptor TWEAK Protein and Its Receptor Fn14 in Human Endometrial Cancer

Conditions
-----------------
Endometrial Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women aged 18 years or older having a hysterectomy for the treatment of endometrial cancer, fibroids, chronic pelvic pain or abnormal uterine bleeding have provided informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Grade 2<br>Patients with Endometrial cancer of Grade 1 differentiation | |
| Benign<br>Patients without endometrial cancer | |
| Grade 1<br>Patients with Endometrial cancer of Grade 2 differentiation | |
| Grade 3<br>Patients with Endometrial cancer of Grade 3 differentiation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hysterectomy, Endometrial cancer, Benign, Endocrine system, Tissue collection
Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.

Study Overview
=================
Brief Summary
-----------------
Dose-response in Japanese patients with postmenopausal osteoporosis.

Official Title
-----------------
Bone Mineral Density Increase and Safety of TSE-424 Compared to Placebo in Osteoporotic Postmenopausal Women

Conditions
-----------------
Postmenopausal Osteoporosis

Intervention / Treatment
-----------------
* Drug: Bazedoxifene
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be postmenopausal and diagnosed as osteoporosis based on bone mineral density and/or vertebral fracture. Exclusion Criteria: Diseases which possibly induce secondary osteoporosis or osteopenia and affect on bone metabolism.

Ages Eligible for Study
-----------------
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Bazedoxifene|nan|
|Drug: Placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone mineral density of lumbar spine (L1-L4) at 2 years. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone metabolic makers, bone fracture, bone mineral density of lumbar spine (L2-L4) and lip, lipid parameters, height and adverse events. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postmenopausal Osteoporosis
Vitamin D Metabolism and the Williams Syndrome

Study Overview
=================
Brief Summary
-----------------
The Williams syndrome is a disease in which supravalvular aortic stenosis, an elfin facies, mental retardation and other congenital defects are sometimes associated with abnormal vitamin D and calcium metabolism. Whereas some patients have been reported to show increased sensitivity to vitamin D or an exaggerated response of serum 25-hydroxyvitamin D {25(OH)D} to administration of vitamin D and to have hypercalcemia caused by increased circulating 1,25-dihydroxyvitamin D{1,25(OH)2D} in infancy and early childhood, most patients have normal calcium metabolism and normal values for circulating 25(OH)D and 1,25(OH)2D. We propose to carry out further studies of vitamin D metabolism to elucidate the mechanism(s) for abnormal vitamin D metabolism. We will determine the response of serum 1,25(OH)2D to administration of 1,25(OH)2D3. Measurement of the 1,25(OH)2D in the patients compared to normal subjects will be the primary outcome.

Official Title
-----------------
Vitamin D Metabolism and the Williams Syndrome

Conditions
-----------------
Williams Syndrome

Intervention / Treatment
-----------------
* Drug: Vitamin D


Participation Criteria
=================
Eligibility Criteria
-----------------
Age 18 years to 50 years of age, patients and normal subjects

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Vitamin D|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Comparison of Length Gain Between Square Flap and Z-plasty in Post Burn Contracture Release

Study Overview
=================
Brief Summary
-----------------
the purpose of this study is to compare the gain in length after postburn contracture release using two different techniques, the more commonly practised z - plasty and relatively newer technique, square flap

Official Title
-----------------
Comparison of Length Gain Between Square Flap and Z-plasty in Post Burn Contracture Release

Conditions
-----------------
Burn Scar

Intervention / Treatment
-----------------
* Procedure: z-plasty
* Procedure: square flap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:- • Both genders. Joints supple. Linear contracture bands. Age between 5years to 50 years. Surrounding non scarred skin. Contractures of axilla, cubital fossa, popliteal fossa and digits. Exclusion Criteria: Deep burns. Joint contractures. Surrounding skin scarred. Broad, irregular contracture. Neck, Perineal, wrist or toe contractures

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Participants are assigned to one of two or more groups in parallel for the duration of the study
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: z-plasty<br>Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed. | Procedure: z-plasty<br>* Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.<br>|
| Experimental: square flap<br>Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed. | Procedure: square flap<br>* Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gain in length | calculation of the gain in length achieved after the release of post burn contrature | 3 weeks |
Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Study Overview
=================
Brief Summary
-----------------
This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.

Detailed Description
-----------------
This is a one-arm, open-label study to examine the effect of Tildrakizumab. Tildrakizumab is a FDA-approved medication for the treatment of cutaneous psoriasis. This study will examine how Tildrakizumab affects immune cells within psoriatic skin lesions. Fifteen subjects with moderate to severe psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with and to predict Tildrakizumab treatment response.

Official Title
-----------------
Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Conditions
-----------------
Psoriasis Vulgaris

Intervention / Treatment
-----------------
* Biological: Tildrakizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female ≥18 years of age at clinic visit. Documentation of moderate-severe psoriasis or atypical psoriasis. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. Exclusion Criteria: Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data Tuberculosis, active serious infection, active systemic malignancy, Received a systemic medication for psoriasis within 3 months of study screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tildrakizumab treatment<br> | Biological: Tildrakizumab<br>* IL-23 inhibitor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Psoriasis Area and Severity Index (PASI) Score from Baseline to 3 months | Change in severity and extent of psoriasis (calculated by Psoriasis Area and Severity Index (PASI) score); scale range of 0 to 72, 72 being maximal disease. | baseline and 3 months |
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia

Study Overview
=================
Brief Summary
-----------------
The purpose of this reseach study is to determine Mölnlycke Health Care´s Leia dressing performance properties is fulfilled and that the dressing is safe when used on wound types such as pressure ulcer, leg ulcer, and diabetic foot ulcer.

Official Title
-----------------
An Open Randomised, Prospective, Crossover, Proof of Concept (Design Validation) Clinical Investigation to Caompare the Performance and Safety of Wound Dressing(Leia) Compared to and Hydroactive Surgical Dressing on Low to Highly Exuding Wounds

Conditions
-----------------
Leg Ulcer, Diabetic Foot Ulcer, Pressure Ulcer

Intervention / Treatment
-----------------
* Device: Leia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Low to highly exuding chronic wound(wound history > 2 months) such as Leg Ulcer, Pressure Ulcer Category III to IV or Diabetic Foot Ulcer Male of female, 18 years and above Signed Informed Consent Form Exclusion Criteria: Pregnancy or lactation Wound size not suitable for the wound dressing size Known allergy/hypersensitivity to any of the components in the dressing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Device, dressing<br>Intervention: Device, Leia dressing | Device: Leia<br> <br> * Other names: It is a synergetic combination of a hydroactive surgical dressing;|
| Active Comparator: Dressing , device<br>Intervention: Device: Hydroactive surgical dressing | Device: Leia<br> <br> * Other names: It is a synergetic combination of a hydroactive surgical dressing;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absorption of Wound Exudates. | Absorption capacity measured subjectively: NA/POOR/GOOD/VERY GOOD/EXCELLENT | 2-3 weeks |
Measuring Auto-fluorescence of White Corpuscles for the Early Diagnosis and the Monitoring of Pneumonia in ICU

Study Overview
=================
Brief Summary
-----------------
The diagnosis of pneumonia is challenging in Intensive Care Unit. The auto-fluorescence of white corpuscles is altered during pneumonia. In presence of bacterial growth on lung samples, the measure of autofluorescence of white corpuscles could help the clinicians to discriminate bacterial colonization from acute infection.

Official Title
-----------------
Measuring Auto-fluorescence of White Corpuscles for the Early Diagnosis and the Monitoring of Pneumonia in Intensive Care Units

Conditions
-----------------
Pneumonia

Intervention / Treatment
-----------------
* Other: Autofluorescence of white corpuscle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalization in intensive care units Mechanical ventilation Age > 18 years Collection of a lung sample for bacteriological analysis for the suspicion of a first episode of lung infection. Exclusion Criteria: Refuse to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Autofluorescence of white corpuscle|Measure of auto-fluorescence of white corpuscles cells harvested from tracheal aspirate and/or bronchoalveolar lavages|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pneumonia | Diagnosis of pneumonia (Clinical Pulmonary Infection Score > 6, with assessment of the chest radiography by a blinded investigator) | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Pulmonary Infection Score > 6 |  | day 3 | 
| Acute respiratory distress syndrome | PaO2/FiO2 < 200 with a PEEP > 5 (Berlin definition) | day 90 | 
| Duration of mechanical ventilation |  | day 90 | 
| Intensive Care unit Length of stay |  | day 90 | 
| Mortality |  | day 90 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pneumonia, diagnosis, prognosis, tracheal aspirate, bronchoalveolar lavage
Evaluation of Different Colorectal Cancer Screening Strategies

Study Overview
=================
Brief Summary
-----------------
A large-scale randomized controlled trial was conducted to compare different colorectal neoplasms screening strategies.

Official Title
-----------------
Evaluation of Different Colorectal Cancer Screening Strategies: a Prospective Randomized Trial

Conditions
-----------------
Colorectal Neoplasms

Intervention / Treatment
-----------------
* Diagnostic Test: Fecal immunochemical test
* Diagnostic Test: APCS score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 50-74 years old Informed consent is available Exclusion Criteria: Previous colorectal cancer Previous colorectal resection Previous received cancer-related treatment (except non-melanoma skin cancer) Colonoscopy, sigmoidoscopy, CT colonoscopy, and barium enema were performed within 5 years Fecal occult blood or fecal DNA was performed within one year Symptoms of lower digestive tract diseases requiring colonoscopy include: (1) rectal bleeding occurred more than once in the past 6 months, (2) recorded iron deficiency anemia, and (3) recorded significant weight loss within 6 months (> 10% of baseline weight) Suffering from other diseases that affect the benefit of screening or intolerance to colonoscopy (for example, severe pulmonary disease, end-stage renal disease, end-stage liver disease, severe heart failure or recently diagnosed cancer, except non-melanoma skin cancer)

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Risk score<br> | Diagnostic Test: APCS score<br>* APCS score can concentrate the high-risk population.<br>|
| Active Comparator: Fecal immunochemical test<br> | Diagnostic Test: Fecal immunochemical test<br>* Fecal immunochemical test can concentrate the high-risk population.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection rate | Detection of intestinal lesions in population | up to 30 months |
Buprenorphine Maintenance Protocol - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the efficacy of buprenorphine versus methadone.

Official Title
-----------------
Buprenorphine Maintenance Protocol

Conditions
-----------------
Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: M/F ages 21-50. Opiate dependence according to DSM-IV criteria. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent. Exclusion Criteria: Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and /or nursing women. Dependence on ETOH or benzodiazepines or other sedative/hynotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retention |  |  | 
| Opiate use |  |  | 
| Opiate craving |  |  | 
| Adverse events |  |  |
Escape Phenomenon of the Antihypertensive Therapy Efficacy

Study Overview
=================
Brief Summary
-----------------
A little attention is paid to the AHT efficacy escaping problem, which can be explained by the AHT correction simplicity and rapid achievement of the target BP level. Nevertheless, modern statistic data on the effective AH treatment described above let us assume that AHT correction is either totally absent or is untimely in case of the escape phenomenon development. This could be one of the main reasons for the high prevalence of ineffective AH treatment. The aim of this study is to determine AHT efficacy escape phenomenon timeline and its predictors in hypertensive patients.

Official Title
-----------------
The Role of Ambulatory Blood Pressure Characteristics, Features of the Structural and Functional Vascular Wall State, the Presence and Severity of Obstructive Sleep Apnea Syndrome in Predicting the Escape Phenomenon of the Antihypertensive Therapy Efficacy.

Conditions
-----------------
Arterial Hypertension

Intervention / Treatment
-----------------
* Device: Ambulatory blood pressure measurement device
* Device: Sphygmocor
* Device: VaSera-VS
* Device: Somnocheck


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Arterial hypertension (AH) grade 1-3, stage I-II High compliance during the follow-up period (≥ 85%) Initially achieved target office BP levels while taking 2-3-component AHT Exclusion Criteria: Secondary AH Resistant AH, AH III stage, PAP- therapy, type 2 diabetes mellitus, pregnancy history of low adherence to treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Escape Phenomenon of the Antihypertensive Therapy Efficacy<br>Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT. | Device: Ambulatory blood pressure measurement device<br>* Assessment of the 24-h blood pressure profile<br>* Other names: BpLab;Device: Sphygmocor<br>* Assessment of the arterial stiffness<br>Device: VaSera-VS<br>* Assessment of the arterial stiffness<br>Device: Somnocheck<br>* Assessment of the sleep breath disturbances<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of BP increasing higher the target level when taking the same therapy | Assessment of attenuation of efficacy of previously adequate antihypertensive therapy by using different BP measurement methods | 1-6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease course: assessment of major CVE and death occurrence | Assessment of the disease course depending on the characteristics of 3-6th months of observation | 10 years |